{"commentary":{"count":19,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":8,"podcast":7,"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04970901\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04970901","nct_id":"NCT04970901","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04970901. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive escalating doses (90 µg/kg to 150 µg/kg) of loncastuximab tesirine on Day (D) 1 of each cycle (where each cycle is 21 days).\n\nParticipants will also receive polatuzumab vedotin at a dose of 1.8 mg/kg on D1 of each cycle, infusion will be started one hour after end of loncastuximab tesirine infusion.","label":"Part 1 (Dose Escalation): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C)","type":"EXPERIMENTAL"},{"description":"Participants will receive escalating doses (90 µg/kg to 150 µg/kg) of loncastuximab tesirine on D2 of Cycle (C) 1 and then D1 of all other cycles (where each cycle is 21 days).\n\nParticipants will also receive glofitamab 2.5 mg on C1 D8, 10 mg on C1 D15 and 30 mg for cycles 2-12 D1.\n\nIn addition participants will receive obinutuzumab pre-treatment 1000 mg on C1 D1.","label":"Part 1 (Dose Escalation): Loncastuximab Tesirine + Glofitamab (Arm E)","type":"EXPERIMENTAL"},{"description":"Participants will receive escalating doses (90 µg/kg to 150 µg/kg) of loncastuximab tesirine on Day (D) 1 of each cycle (where each cycle is 21 days).\n\nParticipants will also receive mosunetuzumab 5 mg on C1 D1, 45 mg for C1 D8, C1 D15 and cycles 2-8 D1.","label":"Part 1 (Dose Escalation): Loncastuximab Tesirine + Mosunetuzumab (Arm F)","type":"EXPERIMENTAL"},{"description":"Participants with B-NHL will receive loncastuximab tesirine in combination with polatuzumab vedotin at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.","label":"Part 2 (Dose Expansion): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C)","type":"EXPERIMENTAL"},{"description":"Participants with B-NHL will receive loncastuximab tesirine in combination with glofitamab at the MTD and/or RDE if favorable results of Part 1 are received. In addition participants will receive obinutuzumab pre-treatment 1000 mg on C1 D1.","label":"Part 2 (Dose Expansion): Loncastuximab Tesirine + Glofitamab (Arm E)","type":"EXPERIMENTAL"},{"description":"Participants with B-NHL will receive loncastuximab tesirine in combination with mosunetuzumab at the MTD and/or RDE if favorable results of Part 1 are received.","label":"Part 2 (Dose Expansion): Loncastuximab Tesirine + Mosunetuzumab (Arm F)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-04-30","type":"ESTIMATED"},"conditions":["B-Cell Non-Hodgkin Lymphoma","Relapsed B-Cell Non-Hodgkin Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma"],"enrollment":{"count":154,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Loncastuximab Tesirine","type":"DRUG"},{"name":"Polatuzumab Vedotin","type":"DRUG"},{"name":"Glofitamab","type":"DRUG"},{"name":"Mosunetuzumab","type":"DRUG"},{"name":"Obinutuzumab","type":"DRUG"}],"last_update":"2026-07-17","lead_sponsor":"ADC Therapeutics S.A.","official_title":"A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-03-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)","timeFrame":"Day 1 to Day 21 of Cycle 1, where a cycle is 21 days"},{"measure":"Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)","timeFrame":"Up to approximately 2 years for Arm C and 3 years for Arms E and F"},{"measure":"Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Delay","timeFrame":"Up to approximately 1 year"},{"measure":"Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Interruption","timeFrame":"Up to approximately 1 year"},{"measure":"Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Reduction","timeFrame":"Up to approximately 1 year"},{"measure":"Number of Participants Who Experience a Clinically Significant Change from Baseline in Safety Laboratory Measurements","timeFrame":"Baseline up to approximately 1 year"},{"measure":"Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Signs","timeFrame":"Baseline up to approximately 1 year"},{"measure":"Number of Participants Who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status","timeFrame":"Baseline up to approximately 1 year"},{"measure":"Number of Participants Who Experience a Clinically Significant Change from Baseline in 12-Lead Electrocardiogram (ECG) Measurements","timeFrame":"Baseline up to approximately 1 year"}],"references":[],"start_date":{"date":"2022-06-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","url":"https://clinicaltrials.gov/study/NCT04970901"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04970901"}